Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-12 GEMys in Relapsed or Refractory Solid Tumors
NCT07672483Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of interleukin 12-secreting genetically engineered myeloid cells in solid tumor (2 arms), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at 28 days and Interleukin-12 or Interferon-gamma levels in tumors at 1 week. Started Nov 2026; status: recruiting.
02
Drugs
interleukin 12-secreting genetically engineered myeloid cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07672483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672483.